Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes

被引：0
|
作者：
Ang, L. [1 ]
Kidwell, K. [2 ]
Dillon, B. [3 ]
Reiss, J. [1 ]
Leone, V. [4 ]
Mizokami-Stout, K. [1 ]
Busui, R. [1 ]
机构：
[1] Univ Michigan, Metab Endocrinol & Diabet Div, Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Ann Arbor, MI USA
[4] Univ Michigan, Metab Endocrinol & Diabet Div, Ann Arbor, MI 48109 USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
844
引用
收藏
页码：S406 / S406
页数：1
相关论文
共 50 条
  • [41] Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes
    Moran, A
    Palmas, W
    Field, L
    Bhattarai, J
    Schwartz, JE
    Weinstock, RS
    Shea, S
    [J]. DIABETES CARE, 2004, 27 (04) : 972 - 977
  • [42] Diabetic cardiovascular autonomic neuropathy predicts recurrent cardiovascular diseases in patients with type 2 diabetes
    Kang-Min, L.
    Cha, S. -A.
    Yun, J. -S.
    Lim, T. -S.
    Song, K. -H.
    Moon, S. -D.
    Ahn, Y. -B.
    Ko, S.
    [J]. DIABETOLOGIA, 2016, 59 : S466 - S466
  • [43] Risk factors for cardiovascular autonomic neuropathy in type 2 diabetes mellitus patients
    Semyatichko, E.
    Nemtsova, V.
    Feclina, I.
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 : 110 - 110
  • [44] Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes
    Cha, Seon-Ah
    Yun, Jae-Seung
    Lim, Tae-Seok
    Min, Kyoungil
    Song, Ki-Ho
    Yoo, Ki-Dong
    Park, Yong-Moon
    Ahn, Yu-Bae
    Ko, Seung-Hyun
    [J]. PLOS ONE, 2016, 11 (10):
  • [45] No increased risk of cardiovascular events with dapagliflozin in elderly patients with type 2 diabetes mellitus, cardiovascular disease and hypertension
    Gause-Nilsson, I.
    Sonesson, C.
    Johansson, P. A.
    Johnsson, E.
    [J]. DIABETOLOGIA, 2015, 58 : S362 - S363
  • [46] Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes
    Brown, Alexander
    Gandy, Stephen
    Mordi, Ify R.
    McCrimmon, Rory
    Ramkumar, Prasad G.
    Houston, J. Graeme
    Struthers, Allan D.
    Lang, Chim C.
    [J]. JACC-CARDIOVASCULAR IMAGING, 2021, 14 (02) : 503 - 504
  • [47] Dapagliflozin and Insulin Resistance in Patients with Type 2 Diabetes
    Katz, Arie
    Yeh, Helen
    [J]. DIABETES, 2015, 64 : A304 - A305
  • [48] Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
    Avgerinos, Ioannis
    Liakos, Aris
    Tsapas, Apostolos
    Bekiari, Eleni
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2549 - 2557
  • [49] Correction of anemia by dapagliflozin in patients with type 2 diabetes
    Stefansson, Bergur V.
    Heerspink, Hiddo J. L.
    Wheeler, David C.
    Sjostrom, C. David
    Greasley, Peter J.
    Sartipy, Peter
    Cain, Valerie
    Correa-Rotter, Ricardo
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (12)
  • [50] Renal effects of dapagliflozin in patients with type 2 diabetes
    Thomas, Merlin C.
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2014, 5 (03) : 53 - 61
12345